Jean-charles Fruchart
Basel, BS 4010, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.
Journal: Journal of the American College of Cardiology
Published: April 19, 2024
Lessons from PROMINENT and prospects for pemafibrate.
Journal: Cardiovascular diabetology
Published: February 19, 2024
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Journal: The New England journal of medicine
Published: November 07, 2022
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
Journal: Current atherosclerosis reports
Published: November 11, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Journal: Current atherosclerosis reports
Published: July 17, 2020
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity.
Journal: Nature reviews. Endocrinology
Published: December 05, 2019
Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.
Journal: Scientific reports
Published: November 25, 2019
Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?
Journal: Diabetes & metabolic syndrome
Published: August 14, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Journal: Cardiovascular diabetology
Published: April 24, 2019
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.
Journal: The lancet. Diabetes & endocrinology
Published: October 16, 2018
Last Updated: 09/26/2026